Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net loss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased work related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development




$3,552  General and administrative




6,857  Total operating expenses




10,409Total operating loss




(10,409)Other income and (expense):  Interest income




18  Change in fair value of warrant liabilities




(524)  Other income




-Total other income (expense)




(506)Net loss




$(10,915)Preferred stock dividends and accretion costs




(1,798)Net loss applicable to common stock




$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share




11,986 Condensed Consolidated Balance Sheet Data December 31,20122011(in thousands, unaudited)Cash and cash equivalents




6,397Total assets9,5616,612Accounts payable and accrued expenses1,6382,015Deferred income-200Total liabilities.1,6442,215Total stockholders' equity (deficit)





SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)... , Oct. 8, 2015  The ALS Association, ... ALS Assistive Technology Challenge to revolutionize communication technology solutions ... --> ALS (amyotrophic lateral sclerosis) is ... in the brain and the spinal cord. Eventually, people ... muscle movement, which often leads to total paralysis and ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider ... and other technology-driven industries, announces that it is one of three finalists for the ... Company.” On Thursday, September 25 Talon Innovations was recognized as a nominee for ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
Breaking Biology Technology:
... , SAN MARINO, Calif., Aug. 26 ... drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this ... on August 25 and August 26, and an article published ... Something About Viral Genetics, Inc. (VRAL)," on August 25. , ...
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... , , DURHAM, N.C., Aug. ... that the company will present at investor conferences in New York ... , Kirk Harrington, senior vice president, Warfighter Division and ... Investment Conference in New York on September 9, 2009 at 2:00 ...
Cached Biology Technology:
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
(Date:9/10/2015)... LONDON , Sept. 10, 2015 Report ... thus far not quite delivered upon previous expectations of ... might be the breakthrough year in which wearables begin ... been expected. One of the main reasons is the ... disrupt not only the SmartWatches market, but the overall ...
(Date:9/9/2015)... British Columbia , Sept. 9, 2015 /PRNewswire/ ... numerous organizational and solution-based milestones, furthering the company,s ... perils of online fraud. NuData Security,s ... in enhancing the company,s growth cycle. The product ... learning to determine good user behavior from fraudulent ...
Breaking Biology News(10 mins):
... This news release is available in French . ... in the liver plays a crucial role in pregnancy in mice ... to researchers at the University of Montreal. Mice that were genetically ... unable to create the uterine conditions necessary for establishing and sustaining ...
... the neuronal circuits in the spinal cord of mice that ... legs during walking. The study, published in the journal ... are in control of limb alternation at different speeds of ... these cell populations are missing. Most land animals can ...
... 28, 2013 Mary Ann Liebert, Inc., publishers announces ... , a highly innovative, peer-reviewed journal on this rapidly ... the fall of 2013, and quarterly thereafter in 2014. ... University,s Creative Machines Lab at the Sibley School of ...
Cached Biology News:
Component in MasterPure™ Purification Kits...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Biology Products: